MSH2 and fragile X syndrome: Unfortunately, we could not use the MSH2 transgene re-expression strategy to evaluate the role of MSH2 in de novo methylation in FXS and FRDA cells as we did not observe a decrease in DNA methylation upon MSH2 knockout.